The CAR-HEMATOTOX: ready for prime time

Jan H Frenking^{1

2}, Kai Rejeski^{3

4}

Affiliations

¹ Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
² Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
⁴ Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.

Free article

Editorial

Jan H Frenking et al. Blood Adv. 2025.

Free article

. 2025 Nov 11;9(21):5638-5640.

doi: 10.1182/bloodadvances.2025017509.

Jan H Frenking^{1

2}, Kai Rejeski^{3

4}

¹ Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
² Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
⁴ Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.

No abstract available

Comment on

Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL.
de Boer JW, Keijzer K, van Dorp S, Mutsaers PGNJ, Niezink AGH, van Doesum JA, Serroukh YIM, Muntendam LW, Pulles AE, Kret EJ, Sijs-Szabo A, Oomen J, Demandt AMP, Stevens WBC, Kuipers MT, Pennings ERA, Spanjaart AM, Kersten MJ, Jak M, van Dijk LV, van der Poel MWM, Vermaat JSP, van Meerten T. de Boer JW, et al. Blood Adv. 2025 Nov 11;9(21):5641-5650. doi: 10.1182/bloodadvances.2025016689. Blood Adv. 2025. PMID: 40668622